Lonza FY Revenues: CHF 3.6 billion  (-4%) FY Earnings: CHR 87 million (-44%) Comments: Pharma & Biotech sales, which include Lonza’s custom manufacturing and Bioscience sectors, were down 8% to CHF 1.4 billion. Revenues were impacted by product portfolio optimizations and the initiation of several major projects. The first quarter saw a scheduled production stop for the build-out at the company’s ADC plant in Visp. Its large-scale mammalian cell culture facility in Singapore implemented m...